TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00087191
Drug: EF5
Normalized name: Hb 76(EF5), Met-thr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00182871
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00791310
Drug: Flucis
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG injected i.v
Study: NCT00460473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00143117
Drug: UK-390,957
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04567550
Drug: Topical Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Steroid
Study: NCT04315064
Drug: Treatment with MTX110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will undergo surgery for maximum safe tumor resection with simultaneous placement of a ventricular access device (VAD) into the fourth ventricle or posterior fossa tumor resection cavity.The specific ventricular access device that will be placed is Medtronic Reference number 44102, Medtronic CSF-Ventricular Reservoir Side Inlet, 18 mm.If a patient already has a ventricular access device in place and additional tumor resection is not required, then that patient can proceed with intraventricular chemotherapy infusions after study enrollment. If the patient has metastatic disease in the brain and/or spine without resectable tumor in the posterior fossa, then only catheter and ventricular access device placement will be performed.Enrolled patients will receive 4 infusions per week of panobinostat (MTX110; 0.25 ml of 300 μM = 26.2 μg), per infusion into the ventricular access device for 6 consecutive weeks for a total of 24 infusions.
Study: NCT00263081
Drug: Current lipid-lowering treatment
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.
Study: NCT00982124
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each patient is to receive an initial dose of zoledronic acid of 0.0125 mg per kg body weight, then subsequent doses of zoledronic acid at a dose of 0.025 mg per kg body weight once every 12 to 13 weeks for 104 weeks (total of 8 doses).
Study: NCT00721266
Drug: RO5083945
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered iv, either weekly, every 2 weeks or every 3 weeks, at escalating doses (with a starting dose of 50mg weekly (Part 1)). Recommended dose administered iv, either weekly, every 2 weeks or every 3 weeks (Part 2).
Study: NCT01113710
Drug: Neupro®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neupro® is the exposure/intervention of interest in this non-interventional study.
Study: NCT02542384
Drug: CR845 IV 0.5 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR845 IV 0.5 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided.
Study: NCT02175784
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00739050
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 20mg daily at nights for 12 weeks. Tablets
Study: NCT01710852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00739050
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo daily at nights for 12 weeks. Tablets
Study: NCT00884533
Drug: Rosi XR
Normalized name: Zinc Oxide 20 g in 100 mL TOPICAL LOTION [Stem Cellular CC Cream rosy glow]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosi XR
Study: NCT03336632
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/Kg intravenously D+3, +4
Study: NCT03989115
Drug: RMC-4630
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMC-4630 for oral administration
Study: NCT01563471
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
Study: NCT02947061
Drug: Capecitabine plus Docetaxel
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
Study: NCT01042977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
Study: NCT00488072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo tablet by mouth daily.
Study: NCT03833167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IV infusion on Day 1 of each 42-day cycle
Study: NCT02594241
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
Study: NCT01822678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01905410
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: water for injection
Study: NCT02034071
Drug: DCCR
Normalized name: Diazoxide Choline Controlled-Release
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02034071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00200551
Drug: Cyclosporin, mycophenolate mofetil, antilymphocyte serum and corticoids.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00200551
Drug: Cyclosporin, mycophenolate mofetil, antilymphocyte serum without corticoids.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01291433
Drug: Clodronate placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
Study: NCT04108377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic look of Roflumilast capsule
Study: NCT04148833
Drug: LDE-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDE-Placebo at the dose of 175 mg/m2 IV each 21 days for 6 weeks
Study: NCT03799172
Drug: Echinocandin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care
Study: NCT03799172
Drug: Triazole treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care.~Candidemia was defined as at least one blood culture positive for Candida.
Study: NCT00225043
Drug: Epinephrine/phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03467412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intradermal injection
Study: NCT00049634
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00049634
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01082731
Drug: Artemether-Lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
Study: NCT04670757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT00006129
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04315935
Drug: Fentanyl and Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fentanyl (0.7-10 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
Study: NCT00337350
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo for rosiglitazone 4mg/day
Study: NCT00014404
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01967758
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 3-day course of oral amoxicillin (500 mg three times per day) or trimethoprim/sulfamethoxazole in penicillin-allergic patients (160 mg trimethoprim / 800mg sulfamethoxazole at 12 hour intervals) will be initiated for each patient 3 days following each dose of ADU-623. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
Study: NCT01164540
Drug: Rosuvastatin (AZD4522)
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral dose (od) 20 mg
Study: NCT01164540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose (od)
Study: NCT03588299
Drug: BAY2599023 (DTX201)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single escalating doses with 4 dose steps; Single intravenous (IV) administration.
Study: NCT03335020
Drug: Contrast-Enhanced Ultrasound
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be done using Lumason (Bracco Diagnostics, Inc) administered intravenously via slow hand infusion. Real-time contrast-enhanced carotid cine-loop (longitudinal and short axis) images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the determined artery will be acquired and digitally stored for off line analysis. Up to two vials will be used for a study.
Study: NCT03176758
Drug: General anesthetic
Normalized name: General anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
Study: NCT04639466
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IM in the non-dominant upper arm
Study: NCT03729973
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized by compressor nebulizing 5ml normal saline for 15 minutes.
Study: NCT03155997
Drug: Standard Adjuvant Endocrine Therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered according to label instructions.
Study: NCT00976170
Drug: GC33(RO5137382)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration at 6 escalating dose levels.
Study: NCT03862716
Drug: IDegLira
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose is titrated to achieve fasting normoglycemia
Study: NCT01859325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00727831
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00727831
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03858231
Drug: Norco 5Mg-325Mg Tablet
Normalized name: Norco 5mg-325mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet up to 4 times per day for 7 days
Study: NCT03858231
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet up to 4 times per day for 7 days
Study: NCT03858231
Drug: Acetaminophen 325Mg Tab
Normalized name: ACETAMINOPHEN 325MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet up to 4 times per day for 7 days
Study: NCT06025851
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT04440982
Drug: LUM015
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.
Study: NCT02356965
Drug: Placebo (for Ketamine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual sugar pill developed to mimic ketamine sublingual dose.
Study: NCT00062673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02927262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT04121416
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: induction with 0.3 µg/kg of Sufentanil in general anesthesia
Study: NCT03412071
Drug: Topical Clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Please see description under arms
Study: NCT00586066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive comparator. Placebo-matching memantine tablet.
Study: NCT03191240
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00208299
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.14 mg/kg/min for 6 minutes, intravenous infusion
Study: NCT02896868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT00986479
Drug: AZD6765
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion of 150 mg AZD6765.
Study: NCT00986479
Drug: Placebo to AZD6765
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion of Placebo to AZD6765
Study: NCT00484718
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral, 100 mg bid
Study: NCT02542384
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided.
Study: NCT00484718
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral bid
Study: NCT04317833
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo
Study: NCT01350154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose monohydrate oral in gelatine capsules, 3 times daily
Study: NCT02999399
Drug: Deuterated Phenanthrene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are given 1 microgram of deuterated phenanthrene \[D10\]phe at baseline and after 7 days of Brussels sprout consumption. Urine is collected for 6 hours after each dose.
Study: NCT00415532
Drug: Medical Standard of Care for ITP
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00311662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet once daily for 12 weeks
Study: NCT03652961
Drug: DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive methotrexate or remain on pre-existing conventional synthetic disease-modifying anti-rheumatic drug (DMARD) if already prescribed.
Study: NCT00062556
Drug: Niacin Extended Release and Lovastatin Tablets
Normalized name: lovastatin / niacin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02125578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will receive placebo every other week or every 4 weeks.
Study: NCT02583373
Drug: CAL02 High-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion
Study: NCT02583373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered administered 2 times (24 hours apart) as i.v. infusion
Study: NCT04629885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo gel with identical appearance to the test product, used as reference treatment.
Study: NCT03165734
Drug: Physician's Choice medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's Choice medications will be selected and administered according to the investigator's judgement. Investigators can select individual P/C agents but cannot combine agents or give them sequentially.
Study: NCT04233034
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill manufactured to mimic verapamil 120mg tablet
Study: NCT00401856
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg oral route
Study: NCT00401856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is identical to eplerenone but the active ingredient is absent
Study: NCT00674973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo matching to erlotinib 150 mg tablet orally once daily.
Study: NCT01951183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO681135 placebo subcutaneously daily
Study: NCT01951183
Drug: RO6811135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously daily
Study: NCT00654303
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02496962
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo were taken daily for 5 days
Study: NCT03034200
Drug: ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: 625mg ONC201 will be given on two consecutive days each week
Study: NCT01050127
Drug: ABT-436
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm Description for details.
Study: NCT01050127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm Description for details.
Study: NCT04012918
Drug: Capecitabine plus aromatase inhibitor
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
Study: NCT00695578
Drug: Biafine
Normalized name: Biafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply to wounds 3 times daily for 4 weeks: ingredients: purified water, liquid paraffin, glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalene, avocado oil, trolamine sodium alginate, cetyl palmitate, methylparaben, sorbic acid, propyl paraben and fragrance.
Study: NCT00752024
Drug: dehydrating agent, haemostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
Study: NCT00054717
Drug: Comparator Protease Inhibitor (CPI)
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04622735
Drug: Paracetamol 500 Mg Oral Tablet X2
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.
Study: NCT04318652
Drug: Methylprednisolone eyedrops
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: instillation of methylprednisolone eye drops
Study: NCT01149616
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml normal saline IV x1
Study: NCT05608590
Drug: Lipiodol UltraFluid
Normalized name: doxorubicin hydrochloride liposome Injection [LipoDox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product is an oil-based contrast medium, Lipiodol® (Guerbet). Lipiodol® is a solution of ethyl esters of iodized fatty acids of poppy seed oil equivalent to 480mg I /ml and is a licensed contrast agent in the Netherlands (RVG 02806, see SmPC D2). The maximum amount of Lipiodol® per HSG procedure is 15 ml.
Study: NCT05945745
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: different treatments based on the molecular analysis
Study: NCT01706692
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: all dosages, frequencies and durations prescribed
Study: NCT04328805
Drug: ibuprofen tablets
Normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tablet
Study: NCT03304821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will self-administer 500 μg/day of a placebo, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of a placebo administered subcutaneously, three times per week for another 3 weeks and then will be followed for another 3 months.